Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2334
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study ; volume:17 ; number:1 ; day:13 ; month:6 ; year:2017 ; pages:1-12 ; date:12.2017
BMC infectious diseases ; 17, Heft 1 (13.6.2017), 1-12, 12.2017

Klassifikation
Medizin, Gesundheit

Beteiligte Personen und Organisationen
Cunningham, Evan B.
Hajarizadeh, Behzad
Dalgard, Olav
Amin, Janaki
Hellard, Margaret
Foster, Graham R.
Bruggmann, Philip
Conway, Brian
Backmund, Markus
Robaeys, Geert
Swan, Tracy
Marks, Philippa S.
Quiene, Sophie
Applegate, Tanya L.
Weltman, Martin
Shaw, David
Dunlop, Adrian
Bruneau, Julie
Midgard, Håvard
Bourgeois, Stefan
Thurnheer, Maria Christine
Dore, Gregory J.
Grebely, Jason
SpringerLink (Online service)

DOI
10.1186/s12879-017-2517-3
URN
urn:nbn:de:1111-2017090611573
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:21 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Cunningham, Evan B.
  • Hajarizadeh, Behzad
  • Dalgard, Olav
  • Amin, Janaki
  • Hellard, Margaret
  • Foster, Graham R.
  • Bruggmann, Philip
  • Conway, Brian
  • Backmund, Markus
  • Robaeys, Geert
  • Swan, Tracy
  • Marks, Philippa S.
  • Quiene, Sophie
  • Applegate, Tanya L.
  • Weltman, Martin
  • Shaw, David
  • Dunlop, Adrian
  • Bruneau, Julie
  • Midgard, Håvard
  • Bourgeois, Stefan
  • Thurnheer, Maria Christine
  • Dore, Gregory J.
  • Grebely, Jason
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis

Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis

Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin

Hochschulschrift

Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin

Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6

Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6

Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin

Hochschulschrift

Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response

Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients

Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis

Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients

Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin

Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report

Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

Verbundene Objekte